A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ

Inclusion Criteria: * Histologically confirmed DCIS by breast core biopsy with a corresponding lesion on breast MRI of at least 1-cm3 in volume. * Patients may have undergone treatment with prior chemotherapy if this was greater than 12 months prior to current diagnosis. * Age \>18 years. * ECOG performance status \<2 (Karnofsky \>60%) * Life expectancy of greater than 12 months. * Normal organ and marrow function as defined below: * leukocytes \>3,000/mcL * absolute neutrophil count \>1,500/mcL * platelets \>100,000/mcL * total bilirubin within normal institutional limits * AST(SGOT) \& ALT(SGPT)within normal institutional limits * creatinine \<1.5 times institutional upper limit of normal or creatinine clearance \>60 mL/min/1.73 m2 * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Pregnancy * Patients who have undergone prior excisional biopsy for DCIS. * Patients who are unable to undergo MRI due to claustrophobia or other reason. * Patients with ipsilateral treatment for DCIS or breast cancer within 12 months prior to entering this study. * Patients receiving any other chemotherapy or investigational agents. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to green tea extracts or sensitivity to green tea. * Uncontrolled concurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.